Net earnings per share for the last 12 months: Tenaya Therapeutics (TNYA)

Symbol and logo of brand tenayatherapeutics.com (TNYA)

Risks for Tenaya Therapeutics (TNYA) are linked to R&D costs and patient recruitment rates. The change in profit per unit over the last 12 months on the GURU.Markets chart shows that the parameter value is -0.49. However, patent protection precludes dumping, while Big Pharma's interest in cardio-pipelines and the success of cardiomyopathy treatment trials confirm the uniqueness of the company's technological platform.

TNYA (tenayatherapeutics.com) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/18/2026

Tenaya Therapeutics Inc (TNYA) - metric breakdowns and financial figures

- company stock exchange capitalization indicators:
General company analysis:tenayatherapeutics.com (TNYA)
Flagship merchandise of Tenaya

Net income per share (TTM) reflects the actual business profitability allocated to a single common share over the last twelve months, excluding the impact of capital structure. By analyzing the change in TTM net income per share, an investor assesses the efficiency of the capital-intensive R&D developments of Tenaya Therapeutics (TNYA), where high patent costs and stringent FDA requirements determine the company's long-term fundamental value.